Reducing cardiovascular risk through treatment of obstructive sleep apnea

2 methodological approaches

Henry Klar Yaggi, Murray A. Mittleman, Dawn Bravata, John Concato, James Ware, Catherine M. Stoney, Susan Redline

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Obstructive sleep apnea (OSA) significantly impacts cardiovascular health, demonstrated by observational investigations showing an independently increased risk of ischemic heart disease, diabetes, hypertension, congestive heart failure, acute coronary syndrome, stroke, cardiovascular mortality, and all-cause mortality. Positive airway pressure (PAP), a medical therapy for sleep apnea, reverses airway obstruction and may help reduce cardiovascular risk. Prior to planning large phase III randomized controlled trials to test the impact of PAP on cardiovascular outcomes, several gaps in knowledge need to be addressed. This article describes 2 independent studies that worked collaboratively to fill these gaps. The populations, design features, and relative benefits/challenges of the 2 studies (SleepTight and BestAIR) are described. Both studies were encouraged to have multidisciplinary teams with expertise in behavioral interventions to improve PAP compliance. Both studies provide key information that will be useful to the research community in future large-scale, event-driven, randomized trials to evaluate the efficacy and/or effectiveness of strategies to identify and treat significant OSA for decreasing risk of major adverse cardiovascular events in high-risk patients.

Original languageEnglish (US)
Pages (from-to)135-143
Number of pages9
JournalAmerican Heart Journal
Volume172
DOIs
StatePublished - Feb 1 2016

Fingerprint

Obstructive Sleep Apnea
Pressure
Mortality
Sleep Apnea Syndromes
Airway Obstruction
Therapeutics
Acute Coronary Syndrome
Compliance
Myocardial Ischemia
Randomized Controlled Trials
Heart Failure
Myocardial Infarction
Hypertension
Health
Research
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Reducing cardiovascular risk through treatment of obstructive sleep apnea : 2 methodological approaches. / Yaggi, Henry Klar; Mittleman, Murray A.; Bravata, Dawn; Concato, John; Ware, James; Stoney, Catherine M.; Redline, Susan.

In: American Heart Journal, Vol. 172, 01.02.2016, p. 135-143.

Research output: Contribution to journalArticle

Yaggi, Henry Klar ; Mittleman, Murray A. ; Bravata, Dawn ; Concato, John ; Ware, James ; Stoney, Catherine M. ; Redline, Susan. / Reducing cardiovascular risk through treatment of obstructive sleep apnea : 2 methodological approaches. In: American Heart Journal. 2016 ; Vol. 172. pp. 135-143.
@article{dda8903ae90145e7a2807e8d23e8318f,
title = "Reducing cardiovascular risk through treatment of obstructive sleep apnea: 2 methodological approaches",
abstract = "Obstructive sleep apnea (OSA) significantly impacts cardiovascular health, demonstrated by observational investigations showing an independently increased risk of ischemic heart disease, diabetes, hypertension, congestive heart failure, acute coronary syndrome, stroke, cardiovascular mortality, and all-cause mortality. Positive airway pressure (PAP), a medical therapy for sleep apnea, reverses airway obstruction and may help reduce cardiovascular risk. Prior to planning large phase III randomized controlled trials to test the impact of PAP on cardiovascular outcomes, several gaps in knowledge need to be addressed. This article describes 2 independent studies that worked collaboratively to fill these gaps. The populations, design features, and relative benefits/challenges of the 2 studies (SleepTight and BestAIR) are described. Both studies were encouraged to have multidisciplinary teams with expertise in behavioral interventions to improve PAP compliance. Both studies provide key information that will be useful to the research community in future large-scale, event-driven, randomized trials to evaluate the efficacy and/or effectiveness of strategies to identify and treat significant OSA for decreasing risk of major adverse cardiovascular events in high-risk patients.",
author = "Yaggi, {Henry Klar} and Mittleman, {Murray A.} and Dawn Bravata and John Concato and James Ware and Stoney, {Catherine M.} and Susan Redline",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.ahj.2015.07.033",
language = "English (US)",
volume = "172",
pages = "135--143",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Reducing cardiovascular risk through treatment of obstructive sleep apnea

T2 - 2 methodological approaches

AU - Yaggi, Henry Klar

AU - Mittleman, Murray A.

AU - Bravata, Dawn

AU - Concato, John

AU - Ware, James

AU - Stoney, Catherine M.

AU - Redline, Susan

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Obstructive sleep apnea (OSA) significantly impacts cardiovascular health, demonstrated by observational investigations showing an independently increased risk of ischemic heart disease, diabetes, hypertension, congestive heart failure, acute coronary syndrome, stroke, cardiovascular mortality, and all-cause mortality. Positive airway pressure (PAP), a medical therapy for sleep apnea, reverses airway obstruction and may help reduce cardiovascular risk. Prior to planning large phase III randomized controlled trials to test the impact of PAP on cardiovascular outcomes, several gaps in knowledge need to be addressed. This article describes 2 independent studies that worked collaboratively to fill these gaps. The populations, design features, and relative benefits/challenges of the 2 studies (SleepTight and BestAIR) are described. Both studies were encouraged to have multidisciplinary teams with expertise in behavioral interventions to improve PAP compliance. Both studies provide key information that will be useful to the research community in future large-scale, event-driven, randomized trials to evaluate the efficacy and/or effectiveness of strategies to identify and treat significant OSA for decreasing risk of major adverse cardiovascular events in high-risk patients.

AB - Obstructive sleep apnea (OSA) significantly impacts cardiovascular health, demonstrated by observational investigations showing an independently increased risk of ischemic heart disease, diabetes, hypertension, congestive heart failure, acute coronary syndrome, stroke, cardiovascular mortality, and all-cause mortality. Positive airway pressure (PAP), a medical therapy for sleep apnea, reverses airway obstruction and may help reduce cardiovascular risk. Prior to planning large phase III randomized controlled trials to test the impact of PAP on cardiovascular outcomes, several gaps in knowledge need to be addressed. This article describes 2 independent studies that worked collaboratively to fill these gaps. The populations, design features, and relative benefits/challenges of the 2 studies (SleepTight and BestAIR) are described. Both studies were encouraged to have multidisciplinary teams with expertise in behavioral interventions to improve PAP compliance. Both studies provide key information that will be useful to the research community in future large-scale, event-driven, randomized trials to evaluate the efficacy and/or effectiveness of strategies to identify and treat significant OSA for decreasing risk of major adverse cardiovascular events in high-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=84959296108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959296108&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2015.07.033

DO - 10.1016/j.ahj.2015.07.033

M3 - Article

VL - 172

SP - 135

EP - 143

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -